Harel Issuances: What Series 21 Actually Is
The main article already showed that Harel Issuances is a capital conduit for Harel Insurance. This follow-up isolates Series 21 and shows why it is not plain debt: it is an Additional Tier 1 instrument with coupon-cancellation terms, principal write-down mechanics, and fair-value accounting that changes the entire read.
What This Follow-up Is Isolating
The main article already argued that Harel Issuances should not be read through its tiny net profit line. It is a financing wrapper serving Harel Insurance. This follow-up isolates Series 21 because calling it "just another bond series" misses the whole point. This is not just another debt layer. It is an Additional Tier 1 instrument issued through the listed financing vehicle, so its coupon, duration, risk profile, and accounting treatment are fundamentally different.
That matters now for a simple reason. By the end of 2025, Series 21 already sat at a carrying value of NIS 1.084 billion and had become the largest series in the stack. But it does not resemble the issuer's regular debt layers. Anyone reading the 5.85% coupon, the June 2074 legal maturity, or the NIS 94.262 million fair-value movement as though this were ordinary debt will misread both the instrument and the issuer.
This is the core distinction: Series 21 looks like a very long bond from the outside, but structurally it behaves like loss-absorbing regulatory capital.
This Is Not Just Another Series In The Stack
The fastest way to see the structure is to compare Series 21 with Series 22, which appears right next to it in the same section of the annual report. Both were issued in 2025, both sit in the same issuer, but they are not in the same category.
| Feature | Series 21 | Series 22 | Why it matters |
|---|---|---|---|
| Stated coupon | 5.85% fixed | 4.8% fixed | Series 21 pays more, but its coupon is not as hard-wired as plain debt |
| Legal maturity | June 30, 2074 | December 31, 2037 | Series 21 was built as a very long capital layer, not as standard refinancing debt |
| Call schedule | June 30, 2035, June 30, 2040, and then every 5 years | From December 31, 2031 on each interest date | The economic life of Series 21 is much more open-ended |
| Structural role | Recognized as Additional Tier 1 capital of Harel Insurance | No such recognition | Series 21 supports the insurer's regulatory capital, not only its funding plan |
| Measurement in the statements | Fair value | Amortized cost of NIS 149.874 million | Series 21 injects accounting volatility that a regular bond series does not |
That comparison does most of the work. Series 22 is still relatively conventional debt with a clearer cash-flow profile. Series 21 is capital wrapped in bond form. That is why coupon and final maturity cannot be read in isolation.
The Coupon Is Not A Hard Promise
On the surface, the terms look familiar: a fixed 5.85% annual coupon, semiannual payments beginning on December 31, 2025, and bullet principal in June 2074. But one clause changes the entire read. The company states explicitly that Series 21 interest payments may be canceled if the instrument's "cancellation circumstances" occur. Beyond that, under certain conditions the company may perform a full or partial write-down of principal and may even defer principal payment.
That is already outside the world of plain debt. The holder is not just exposed to a cash-flow promise. The holder sits inside a capital layer designed to absorb stress if needed. That is why the headline coupon is not enough. It must be read together with the cancellation mechanism, the principal write-down option, and the fact that the instrument was recognized by the supervisor as Additional Tier 1 capital of Harel Insurance.
The ratings tell the same story. At the end of November 2025, S&P raised Harel Insurance itself to ilAAA/stable, while Series 21 was raised only to ilAA-. So even after the upgrade, the instrument still did not sit at the same level as the insurer. That is exactly what one should expect from a structure like this: strong parent credit does not erase the instrument's contractual subordination and loss-absorption design.
Midroog's monitoring report on Harel Insurance adds a useful structural lens here. It does not discuss Series 21 explicitly, but it describes subordinated capital instruments through three elements: legal and contractual subordination, ranking within the capital stack, and embedded loss-absorption mechanisms. That is the right language for Series 21 as well. It should not be read as a long-dated coupon alone, but as a capital instrument whose structure matters as much as the stated rate.
Why The Accounting Moved To Fair Value
This is where the analysis becomes more interesting. In the accounting-policy note, the company explains that the matching deposit against Series 21 does not qualify for amortized-cost treatment because under certain trigger events it can be written down on a back-to-back basis against the liability. In other words, even on the asset side this is no longer a simple principal-and-interest cash-flow asset. So the deposit is measured at fair value through profit or loss.
On the liability side, the company also designated Series 21 at fair value through profit or loss in order to avoid an accounting mismatch against that matching deposit. That sounds technical, but it is actually a structural disclosure. The company is effectively saying that this instrument no longer fits naturally inside the ordinary debt bucket. If both the asset and the liability have to move to fair value to reflect the same write-down mechanics, the structure is already telling the reader what it really is.
The numbers are sharp. At December 31, 2025, Series 21 had an amortized cost of NIS 989.938 million, but the carrying value already stood at NIS 1.0842 billion after a NIS 94.262 million fair-value adjustment. At the same time, the matching deferred deposit against Harel Insurance was carried at the same NIS 1.0842 billion.
That also explains why the income statement jumped in 2025 without creating a new earnings engine. The company recorded NIS 94.262 million of finance income from fair-value changes in the asset, and at the same time NIS 94.262 million of finance expense from fair-value changes in the liability. The big number is not a spread story. It is an accounting mirror meant to reflect the instrument's structure.
That point matters especially for anyone trying to read Harel Issuances from the top lines of the P&L. Without understanding Series 21, it is easy to mistake a structural remeasurement for new recurring economics. That is not what happened here.
What This Changes In The Read Of The Issuer
Once Series 21 is recognized as Additional Tier 1, the real question is no longer only how much it raised or what coupon it carries. The real question is how the entire issuer should be read now that this series sits at the center of the stack. The answer is that Harel Issuances becomes even less like a regular bond issuer and even more like a conduit translating Harel Insurance capital quality into a tradable market instrument.
That changes the analysis on three levels. First, the hierarchy of risk inside the stack becomes sharper: Series 21 is the point where the holder is no longer sitting only against cash flow, but also against loss-absorption mechanics. Second, the relevant performance test shifts away from the issuer's net profit and toward Harel Insurance's distance from the zones where coupon cancellation or write-downs stop being theoretical background. Third, year-end carrying value itself becomes a structural reading, not a plain debt reading. When Series 21 sits at NIS 1.084 billion of carrying value, that does not simply mean "more debt." It means the regulatory-capital layer is now large enough to reshape how the whole issuer should be interpreted.
The practical implication is straightforward. As long as Harel Insurance remains on the right side of capital strength, ratings, and market access, Series 21 is an efficient capital tool. But if that distance starts to narrow, this is exactly the series that reminds the reader Harel Issuances is not only a debt conduit. It is also a conduit for loss-absorbing capital.
Conclusion
Series 21 is not just another long bond. It is a regulatory-capital instrument dressed in bond form, and it has to be read that way.
The 5.85% coupon, the 2074 legal maturity, and the NIS 1.084 billion carrying value are only the shell. The real core sits elsewhere: possible coupon cancellation, possible principal write-down, extreme tenor, and financial statements in which both the asset and the liability move through fair value because that is what the loss-absorption structure requires.
That is why Series 21 changes the whole read on Harel Issuances. Not because another big debt series was added, but because a genuine capital layer was added, and that forces the reader to distinguish between ordinary debt and a true loss-absorbing capital instrument.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.